Why the study?
Coronary artery ectasia is increasingly recognized as an active substrate for ACS rather than an incidental angiographic finding, yet percutaneous coronary intervention is technically challenging and the optimal long-term antithrombotic strategy remains unresolved.
Coronary artery ectasia is an active substrate for acute coronary syndrome present in 0.9% to 10% of ACS patients, where percutaneous coronary intervention is technically challenging and the optimal long-term antithrombotic strategy remains unresolved.
Answers are grounded in this paper and cite their sources.
Should not routinely add oral anticoagulation in coronary artery ectasia with acute coronary syndrome; leaves open optimal antithrombotic strategies for dedicated trials.
Coronary artery ectasia (CAE) is an uncommon coronary arteriopathy characterized by diffuse or segmental dilatation of an epicardial coronary artery to at least 1.5 times the diameter of an adjacent normal segment. Although traditionally regarded as an incidental angiographic finding, CAE is increasingly recognized as an active substrate for acute coronary syndrome (ACS). Abnormal vascular remodeling, extracellular matrix degradation, endothelial dysfunction, and disturbed flow promote stasis, platelet activation, intraluminal thrombosis, and distal embolization, so myocardial infarction may occur even without a critical obstructive lesion. CAE is reported in approximately 0.9% to 10% of patients with ACS and most frequently involves the right coronary artery. The Markis classification describes anatomical extent, with diffuse and multivessel phenotypes appearing to confer greater thrombotic risk. Coronary angiography remains the diagnostic cornerstone, whereas intravascular ultrasound and optical coherence tomography define vessel-wall pathology, thrombus burden, and stent apposition. Management follows established ACS principles, and percutaneous coronary intervention is technically challenging. The optimal long-term antithrombotic strategy remains unresolved; only one small randomized controlled trial is available, and it did not show a clear benefit of adding oral anticoagulation to antiplatelet therapy, while observational studies do not support routine anticoagulation. Adequately powered multicenter trials are needed to define risk stratification and optimal treatment.
No takes yet. Share an insight, caveat, or question.
Candela et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: